Trial Profile
A Phase 2 Randomized, Single-Blind Study of a Single Dose of Peginterferon Lambda-1a (Lambda) Compared With Placebo in Outpatients With Mild COVID-19
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 May 2021
Price :
$35
*
At a glance
- Drugs Peginterferon lambda-1a (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
- Acronyms COVID-Lambda
- 19 May 2021 Status changed from active, no longer recruiting to completed.
- 28 Sep 2020 Results presented in an Eiger BioPharmaceuticals media release.
- 24 Sep 2020 Planned End Date changed from 31 May 2022 to 1 May 2021.